GlaxoSmithKline’s Consumer Healthcare business will operate under the name Haleon when it demerges from the larger group later this year.
The name Haleon, GSK explained, was inspired by the merging of the words “Hale” – an old English word that...
EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year
Listen to this article
Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.
Explore how consumer health is evolving. On the go.
More from Europe
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
• By
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
More from Geography
• By
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.